



IPO NOTE

MANIPAL HEALTH ENTERPRISES LIMITED



Rating:

AVOID



ISSUE OFFER

Issue Opens on	JULY 29, 2026
Issue Close on	JULY 31, 2026
Total IPO size (cr)	₹9,275
Fresh issue (cr)	₹8,000
Offer For Sale (cr)	₹1,275
Price Band (INR)	₹560-590
Market Lot	25 SHARES
Face Value (INR)	₹2
Listing At	BSE, NSE
Market Cap (Pre IPO)	₹77,605.68 CR.

ISSUE BREAK-UP (%)

QIB Portion		75%
NII Portion		15%
Retail Portion		10%

INDICATIVE TIMETABLE

Basis of Allotment	03-08-2026
Refunds/Unblocking ASBA Fund	04-08-2026
Credit of Share to Demat A/c	04-08-2026
Listing Date	05-08-2026

Manipal Health Enterprises Limited is a healthcare service providers, operating a large network of multi-specialty hospitals, clinics, and diagnostic centres across the country.


OBJECTS OF THE ISSUE

- Repayment of outstanding debt and accrued interest of its subsidiary, Manipal Hospitals Private Limited.
- Acquisition of the minority stake in subsidiary Sahyadri Hospitals Private Limited.

FINANCIALS (RESTATED CONSOLIDATED)

PARTICULARS (IN CRORE)	FY 2026	FY 2025	FY 2024
Equity Share Capital	235.95	77.06	75.63
Net Worth	8,440.92	5,865.66	4,029.22
Revenue from operations	10,335.75	8,242.25	6,171.63
EBITDA Margin%	25.58%	26.27%	27.49%
Net Profit/Loss of the year	916.52	1,081.67	533.20

FINANCIAL RATIOS OF FY26



OUTLOOK & VALUATION

- IPO funds mainly to repay acquisition debt, leaving limited capital for future expansion.
- High dependence on Karnataka, with 46–60% of revenue coming from hospitals in the state.
- Premium valuation, with the IPO priced at or above the top end of peer valuations.
- Limited margin of safety for investors due to the expensive valuation.
- Wait for better entry levels after listing or clearer signs of debt reduction before considering an investment.



COMPANY PROFILE

- India's largest pan-India multispecialty hospital network by bed capacity – 13,037 licensed beds, 49 hospitals as of FY26, with metro leadership in Bengaluru, Kolkata and Pune.
- It operates a network of multi-speciality hospitals offering clinical services across several specialties, with a focus on tertiary and quaternary care such as cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics and renal sciences.
- The company operates as a single business segment focused on medical and healthcare services, combining hospital infrastructure, clinical expertise and diagnostic capabilities to deliver care.
- Expands by acquiring hospitals, helping it increase its presence in new cities and serve more patients. The company has expanded through acquisitions such as Columbia Asia, AMRI, Medica, and Sahyadri hospitals.



COMPETITIVE STRATEGIES

- Continue capitalizing growth opportunities in existing facilities and organic network expansion.
- Strategic acquisitions to enter and consolidate market positions and improve access and patient care.
- Leverage digital, AI and technology to extend patient reach and access, transform patient and clinician experiences, expand out-of-hospital care and continue to focus on operational excellence to drive efficiencies.
- Continue to attract, develop and retain medical talent.
- Invest in advanced medical infrastructure and clinical innovations



KEY CONCERNS

- High dependence on Karnataka, which contributes nearly 46% of revenue.
- Revenue relies heavily on inpatient admissions; lower occupancy can hurt earnings.
- Over 64% of inpatient revenue comes from key specialties (CONGO-R); weaker demand is a risk.
- Part of the IPO proceeds will be used to repay subsidiary debt (NCDs).
- Around 50% of inpatient revenue comes from insurance and TPAs; payment delays or contract issues could affect cash flows.



KEY STRENGTHS

- India's largest multispecialty hospital group by bed capacity with pan-India presence and leadership in its three key regions.
- The company is the only private hospital chain network in India with leadership in three metros (Bengaluru, Kolkata and Pune) with a balanced and diversified presence across metros and non-metros.
- Widely recognized brand and network of choice for patients, doctors and healthcare professionals.
- Advanced infrastructure and medical equipment, with a strong focus on clinical excellence.

COMPARISON WITH LISTED INDUSTRY PEERS

Name of the Company	EPS (₹ Basic)	P/E	NAV	Revenue (cr.)	RoNW%
Manipal Health Enterprises Ltd.	7.71		72.55	366.01	10.57
Peer Group					
Apollo Hospitals Enterprise Ltd	135.04	66.15	-	341.99	-
Fortis Healthcare Ltd	13.80	70.22	-	1,424.28	-
Max Healthcare Institute Ltd	14.83	74.55	-	16,402.70	-



DISCLAIMER:

The information contained herein are strictly confidential and are meant solely for the information of the recipient and shall not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written permission of Swastika Investmart Ltd. ("SIL"). The contents of this document are for information purpose only. This document is not an investment advice and must not alone be taken as the basis for an investment decision. Before taking any decision to invest, the recipient of this document must read carefully the Red Herring Prospectus ("RHP") issued to know the details of IPO and various risks and uncertainties associated with the investment in the IPO of the Company. All recipients of this document must before acting on the given information/details, make their own investigation and apply independent judgment based on their specific investment objectives and financial position. They can also seek appropriate professional advice from their own legal and tax consultants, advisors, etc. to understand the risks and investment considerations arising from such investment. The investor should possess appropriate resources to analyze such investment and the suitability of such investment to such investor's particular circumstances before making any decisions on the investment. The investor shall be solely responsible for any action taken based on this document. SIL shall not be liable for any direct or indirect losses arising from the use of the information contained in this document and accept no responsibility for statements made otherwise issued or any other source of information received by the investor and the investor would be doing so at his/her/its own risk. The information contained in this document should not be construed as forecast or promise or guarantee or assurance of any kind. The investors are not being offered any assurance or guaranteed or fixed returns on their investments. The users of this document must bear in mind that past performances if any, are not indicative of future results. The actual returns on investment may be materially different than the past. Investments in Securities market products and instruments including in the IPO of the Company are highly risky and they are generally not an appropriate avenue for someone with limited resources/ limited investment and low risk tolerance. Such Investments are subject to market risks including, without limitation, price, volatility and liquidity and capital risks. Therefore, the users of this document must carefully consider all the information given in the RHP including the risks factors before making any investment in the Equity Shares of the Company.

Swastika Investmart Ltd or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Swastika Investmart Ltd nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Swastika Investment Ltd may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the Subject Company or third party in connection with the Research Report.

CORPORATE & ADMINISTRATIVE OFFICE - 48, Jaora Compound, M.Y.H. Road, Indore - 452 001 | Phone 0731 - 6644000

Compliance Officer: Mrs. Dimple Soni Email: compliance@swastika.co.in Phone: (0731) 6644 241

Swastika Investmart Limited, SEBI Reg. No.: NSE/BSE/MSEI: INZ000192732 Merchant Banking: INM000012102 Investment Adviser: INA000009843 MCX/NCDEX: INZ000072532

Research Analyst Reg. No.: INH000024073

CDSL/NSDL: IN-DP-115-2015 RBI Reg. No.: B-03-00174 IRDA Reg. No.: 713.

For additional information & risk factors please refer to the Red Herring Prospectus